Skip to main content

Table 2 Genes under-expressed in patients with JRA

From: Evidence for chronic, peripheral activation of neutrophils in polyarticular juvenile rheumatoid arthritis

GenBank accession no.

Symbol

Description

Avg. control

Avg. patients

Ratio C/P

NM_001145

ANG

Angiogenin, ribonuclease, RNase A family, 5

18.8

6.1

3.1

NM_000041

APOE

Apolipoprotein E

16.9

7.2

2.3

NM_002983

CCL3

chemokine (C-C motif) ligand 3

166.7

7.4

22.4

D90145

CCL3L1

chemokine (C-C motif) ligand 3-like 1

197.7

21.4

9.2

NM_002984

CCL4

chemokine (C-C motif) ligand 4

221.7

22.2

10.0

NM_002985

CCL5

chemokine (C-C motif) ligand 5

38.5

8.3

4.7

NM_001781

CD69

CD69 antigen (p60, early T-cell activation antigen)

23.5

4.5

5.2

NM_004233

CD83

CD83 antigen (activated B lymphocytes, immunoglobulin superfamily)

24.3

0.1

365.9

NM_031226

CYP19A1

cytochrome P450, family 19, subfamily A, polypeptide 1

25.8

9.2

2.8

NM_004408

DNM1

Dynamin 1

13.6

4.1

3.3

NM_004418

DUSP2

Dual specificity phosphatase 2

54.1

7.8

6.9

NM_000114

EDN3

Endothelin 3

36.7

11.8

3.1

NM_001961

EEF2

Eukaryotic translation elongation factor 2

114.1

29.1

3.9

NM_005252

FOS

V-fos FBJ murine osteosarcoma viral oncogene homolog

483.5

100.4

4.8

NM_006732

FOSB

FBJ murine osteosarcoma viral oncogene homolog B

89.6

11.7

7.7

NM_015675

GADD45B

Growth arrest and DNA-damage-inducible, beta

87.5

19.3

4.5

NM_012483

GNLY

Granulysin

47.5

2.5

19.2

NM_006144

GZMA

Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)

15.3

4.5

3.4

NM_019111

HLA-DRA

Major histocompatibility complex, class II, DR alpha

226.5

33.9

6.7

NM_006895

HNMT

Histamine N-methyltransferase

13.4

4.4

3.1

NM_031157

HNRPA1

Heterogeneous nuclear ribonucleoprotein A1

31.8

8.8

3.6

NM_014365

HSPB8

heat shock 22-kDa protein 8

23.8

7.0

3.4

NM_000576

IL1B

Interleukin 1, beta

169.0

22.4

7.5

AK055991

LAMR1

Laminin receptor 1 (67 kDa, ribosomal protein SA)

35.3

14.2

2.5

NM_002305

LGALS1

Lectin, galactoside-binding, soluble, 1 (galectin 1)

15.5

4.3

3.6

X60188

MAPK3

Mitogen-activated protein kinase 3

228.5

81.3

2.8

NM_020529

NFKBIA

Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha

705.4

56.0

12.6

NM_002135

NR4A1

Nuclear receptor subfamily 4, group A, member 1

46.0

15.4

3.0

NM_006186

NR4A2

Nuclear receptor subfamily 4, group A, member 2

35.7

9.5

3.8

U12767

NR4A3

Nuclear receptor subfamily 4, group A, member 3

18.3

4.4

4.2

BC011589

OSM

Oncostatin M

19.8

5.3

3.8

NM_002659

PLAUR

Plasminogen activator, urokinase receptor

23.8

4.8

4.9

NM_000311

PRNP

Prion protein (p27-30)

15.0

5.1

3.0

NM_000963

PTGS2

Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)

174.9

30.4

5.8

NM_002823

PTMA

Prothymosin, alpha (gene sequence 28)

169.0

56.0

3.0

NM_000994

RPL32

Ribosomal protein L32

174.4

58.6

3.0

NM_002966

S100A10

S100 calcium binding protein A10 (annexin II ligand, calpactin I, light polypeptide [p11])

33.9

9.2

3.7

NM_003745

SOCS1

suppressor of cytokine signaling 1, SSI-1

23.1

8.2

2.8

NM_032298

SYT3

synaptotagmin III, DKFZp761O132

30.2

11.4

2.7

NM_003246

THBS1

Thrombospondin 1

33.7

11.1

3.0

NM_006290

TNFAIP3

Tumour necrosis factor, alpha-induced protein 3

112.1

24.9

4.5

NM_003407

ZFP36

Zinc finger protein 36, C3H type, homolog (mouse)

177.8

51.5

3.5

  1. Avg. control, average (normalised) intensity in controls; Avg. patients, average (normalised) intensity in patients; Ratio C/P, fold difference between controls and patients.